NXTC CIK: 1661059

NextCure, Inc.

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25

Assets

(positive)
Change from FY21 to FY25
millions USD
FY21:
228
FY22:
164
FY23:
113
FY24:
71.8
FY25:
43.7
(positive)
Change from FY21 to FY25
millions USD
FY21:
14.6
FY22:
20.2
FY23:
15.3
FY24:
9.05
FY25:
6.44
Total assets
Change from FY21 to FY25
millions USD
FY21:
242
FY22:
184
FY23:
128
FY24:
80.9
FY25:
50.2

Liabilities & Equity

(negative)
Change from FY21 to FY25
millions USD
FY21:
6.61
FY22:
9.13
FY23:
6.88
FY24:
9.57
FY25:
10.6
(negative)
Change from FY21 to FY25
millions USD
FY21:
2.39
FY22:
7.50
FY23:
6.73
FY24:
5.81
FY25:
4.67
(positive)
Change from FY21 to FY25
millions USD
FY21:
233
FY22:
168
FY23:
114
FY24:
65.5
FY25:
34.9
Total liabilities & equity
Change from FY21 to FY25
millions USD
FY21:
242
FY22:
184
FY23:
128
FY24:
80.9
FY25:
50.2

All amounts in millions USD Data source:SEC EDGAR